Eli Lilly's oral JAK inhibitor Olumiant effectively improves pain/body function...

Lilly (Eli Lilly) and partner Incyte recently in the 2021 European College of Rheumatology Annual Meeting (EULAR2021) announced Olumiant oral JAK inhibitor (Ai Leming ^® , generic name: baricitinib, Barry imatinib) treatment of moderate to New post-event analysis data from the Phase 3 clinical study of severe rheumatoid arthritis (RA)

Olumiant is an oral JAK inhibitor, discovered by Incyte and licensed to Eli Lilly

Olumiant is a tyrosine protein kinase (JAK) 1/2 inhibitor, administered orally once a day, suitable for moderate to severe patients with poor efficacy or intolerance to one or more disease-improving anti-rheumatic drugs (DMARD) Adult patients with active rheumatoid arthritis can be used in combination with methotrexate or other non-biological anti-rheumatic drugs

In this post-mortem analysis, 1305 patients from the Phase 3 RA-BEAM study were randomly divided into 3 treatment groups: Olumiant (oral, once a day, 4mg), Humira (injection, once every other week, 40mg) , Placebo, each group received background methotrexate at the same time

A linear regression model was used to establish the relationship between the change in patient reported results (response) at 12 weeks and the CDAI value at 12 weeks (the main explanatory variable) to evaluate the results reported by patients taking 4 mg Olumiant compared with placebo and Humira.

The results of the analysis showed that during the 12 weeks of treatment, compared with Humira and placebo, patients treated with 4mg Olumiant observed greater pain relief and greater improvement in physical function, and the duration of joint stiffness in the morning was reduced

Peter C.

Analyze data after the fact

Olumiant’s active pharmaceutical ingredient is baricitinib, which is a selective and reversible JAK1 and JAK2 inhibitor.

Olumiant is an oral JAK inhibitor, discovered by Incyte and licensed to Eli Lilly

In the treatment of RA, Olumiant's approved doses in the EU are 4mg and 2mg, the dose approved in the United States is 2mg, and the dose approved in China is 2mg

Original source:

OLUMIANT ^® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Ph ase 3 Post-Hoc Analyses

This article is from Bio Valley, for more information, please download the Bio Valley APP (http://